Tenax Therapeutics to Host Virtual R&D Webinar with Scientific Experts Highlighting HELP Study Results
November 06 2020 - 8:30AM
Business Wire
Webinar Scheduled for 4:30 pm EST on November
18
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty
pharmaceutical company focused on identifying, developing and
commercializing products for the critical care market, today
announced that it will host a virtual R&D webinar for analysts
and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST.
Tenax will share updates related to levosimendan and its
recently completed Phase 2 trial for the treatment of patients with
pulmonary hypertension and heart failure with preserved ejection
fraction (PH-HFpEF). The event will feature presentations from
three globally recognized experts in the areas of pulmonary
hypertension and heart failure with preserved ejection fraction, as
well as a Q&A panel discussion. The speakers will include:
- Stuart Rich, MD, Professor of Medicine,
Northwestern University Feinberg School of Medicine
- Daniel Burkhoff, MD, PhD, Director Heart
Failure, Hemodynamics and MCS Research at the Cardiovascular
Research Foundation
- Barry Borlaug, MD, Professor of Medicine,
Mayo Clinic
A live webcast of the Virtual R&D Webinar and accompanying
slides will be available under “Events and Presentations” in the
Investors section of the Company’s website at www.tenaxthera.com.
An archived webinar recording of the event will be available on the
website for approximately 30 days. If you are a member of the
investment community and would like to attend, please RSVP to
stephanie.carrington@westwicke.com.
About Phase 2 HELP Trial
The HELP Study (Hemodynamic Evaluation of Levosimendan in
PH-HFpEF) was a multi-center, double-blind, placebo-controlled
Phase 2 clinical trial designed to evaluate levosimendan in 36
patients with pulmonary hypertension and heart failure with
preserved ejection fraction (PH-HFpEF). Endpoints in the trial
evaluated various invasive hemodynamic and clinical measures
including a 6-minute walk test. The Company previously announced
positive topline results from this Phase 2 trial. The trial
demonstrated significant reduction in right atrial and pulmonary
capillary wedge pressures. It also demonstrated a significant
improvement with 6-minute walk distance.
About Tenax Therapeutics
Tenax Therapeutics, Inc., is a specialty pharmaceutical company
focused on identifying, developing, and commercializing products
that address cardiovascular and pulmonary diseases with high unmet
medical need. The Company has a world-class scientific advisory
team including recognized global experts in pulmonary hypertension.
The Company owns North American rights to develop and commercialize
levosimendan and has recently released topline data regarding their
Phase 2 clinical trial for the use of levosimendan in the treatment
of Pulmonary Hypertension associated with Heart Failure and
preserved Ejection Fraction (PH-HFpEF). For more information, visit
www.tenaxthera.com.
About Levosimendan
Levosimendan is a calcium sensitizer that works through a unique
triple mechanism of action. It initially was developed for
intravenous use in hospitalized patients with acutely decompensated
heart failure. It was discovered and developed by Orion Pharma,
Orion Corporation of Espoo Finland, and is currently approved in
over 60 countries for this indication and not available in the
United States. Tenax Therapeutics acquired North American rights to
develop and commercialize levosimendan from Phyxius Pharma,
Inc.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by
the Company that involve risks and uncertainties and reflect the
Company’s judgment as of the date of this release. The
forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to matters beyond the
Company’s control that could lead to delays in the clinical study,
new product introductions and customer acceptance of these new
products; matters beyond the Company’s control that could impact
the Company’s continued compliance with Nasdaq listing
requirements; the impact of management changes on the Company’s
business and unanticipated charges, costs and expenditures not
currently contemplated that may occur as a result of management
changes; and other risks and uncertainties as described in the
Company’s filings with the Securities and Exchange Commission,
including in its annual report on Form 10-K filed on March 30,
2020, and its quarterly report on Form 10-Q filed on August 14,
2020, as well as its other filings with the SEC. The Company
disclaims any intent or obligation to update these forward-looking
statements beyond the date of this release. Statements in this
press release regarding management’s future expectations, beliefs,
goals, plans or prospects constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201106005042/en/
Investor Contact: Westwicke, an ICR Company Stephanie
Carrington, 646-277-1282 stephanie.carrington@westwicke.com
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Apr 2023 to Apr 2024